Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases
CNR Ibb | back to homepage
CNR Ibb | back to homepage

Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases (586 views)

Portella L, Vitale R, De Luca S, D'Alterio C, Ieranò C, Napolitano M, Riccio A, Polimeno MN, Monfregola L, Barbieri A, Luciano A, Ciarmiello A, Arra C, Castello G, Amodeo P, Scala S

Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2013 Sep 13; 8(9): N/D-N/D.

Export to BibTeX    Export to EndNote

Paper type: Journal Article, Abstract, Conference

Impact factor: 3.534, 5-year impact factor: 4.015

Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84884132303&partnerID=40&md5=434f79a1b7515fbeacb8d1f6eba44719

Keywords: [cysteinyltryptophanylhistidylarginylcysteine], Arginylalanine [cysteinylarginyltyrosyltryptophanylcysteine], Arginylalanine[cysteinylarginylhistidyltryptophanylcysteine], Arginylalanine[cysteinylarginylphenylalanylphenylalanylcysteine], Chemokine Receptor Cxcr4, Cyclopeptide, Mitogen Activated Protein Kinase 1, Plerixafor, Unclassified Drug, Amino Acid Sequence, Animal Cell, Animal Experiment, Animal Model, Article, Calcium Transport, Cancer Cell, Cancer Inhibition, Cell Migration, Controlled Study, Drug Activity, Drug Design, Enzyme Induction, Female, Human, Human Cell, In Vitro Study, In Vivo Study, Kidney Cancer, Lung Metastasis, Melanoma B16, Melanoma Cell, Metastasis Inhibition, Mouse, Nonhuman, Osteosarcoma Cell, Receptor Binding, Tumor Xenograft, Wound Healing, Cell Line, Cell Movement, Cell Proliferation, Chemokine Cxcl12, Drug Screening Assays, Antitumor, Extracellular Signal-Regulated Map Kinases, Lung Neoplasms, Inbred Balb C, Inbred C57bl, Molecular Sequence Data, Phosphorylation, Protein Binding, Arginylalanine [cysteinylarginylhistidyltryptophanylcysteine], Arginylalanine [cysteinylarginylphenylalanylphenylalanylcysteine]

Affiliations:
*** IBB - CNR ***

Department of Oncological Immunology, ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Fondazione Giovanni Pascale-IRCCS-ITALIA, Naples, Italy
Animal Facility, ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Fondazione Giovanni Pascale-IRCCS-ITALIA, Naples, Italy
ICB-CNR, CNR, Pozzuoli, Italy
IBB-CNR, CNR, Naples, Italy
CROM, Mercogliano (AV), Italy
Azienda Sanitaria Locale n 5 Spezzino, La Spezia, Italy


References:
Not available.
Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases

The CXCR4/CXCL12 axis plays a role in cancer metastases, stem cell mobilization and chemosensitization. Proof of concept for efficient CXCR4 inhibition has been demonstrated in stem cell mobilization prior to autologous transplantation in hematological malignancies. Nevertheless CXCR4 inhibitors suitable for prolonged use as required for anticancer therapy are not available. To develop new CXCR4 antagonists a rational, ligand-based approach was taken, distinct from the more commonly used development strategy. A three amino acid motif (Ar-Ar-X) in CXCL12, also found in the reverse orientation (X-Ar-Ar) in the vMIP-II inhibitory chemokine formed the core of nineteen cyclic peptides evaluated for inhibition of CXCR4-dependent migration, binding, P-ERK1/2-induction and calcium efflux. Peptides R, S and I were chosen for evaluation in in vivo models of lung metastases (B16-CXCR4 and KTM2 murine osteosarcoma cells) and growth of a renal cells xenograft. Peptides R, S, and T significantly reduced the association of the 12G5-CXCR4 antibody to the receptor and inhibited CXCL12-induced calcium efflux. The four peptides efficiently inhibited CXCL12-dependent migration at concentrations as low as 10 nM and delayed CXCL12-mediated wound healing in PES43 human melanoma cells. Intraperitoneal treatment with peptides R, I or S drastically reduced the number of B16-CXCR4-derived lung metastases in C57/BL mice. KTM2 osteosarcoma lung metastases were also reduced in Balb/C mice following CXCR4 inhibition. All three peptides significantly inhibited subcutaneous growth of SN12C-EGFP renal cancer cells. A novel class of CXCR4 inhibitory peptides was discovered. Three peptides, R, I and S inhibited lung metastases and primary tumor growth and will be evaluated as anticancer agents.
Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases

No results.
Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases

Filter those results▼
Query:  [X]
Options:
   Extended  
   IBB affiliation
 
Authors:  [X]
Paper type:  [X]
Start date:  [X]
End date:  [X]
Site:
[Clear form]
Select the year: 
Other filter: ([btitle,keywords] "[cysteinyltryptophan ...

Sort by:   date ▼▲   title ▲ ▼   journal ▲ ▼   authors ▲ ▼   I.F. ▲ ▼
Pelagalli A, Nardelli A, Lucarelli E, Zannetti A, Brunetti A
* Autocrine signals increase Ovine Mesenchymal Stem Cells migration through Aquaporin-1 and CXCR4 overexpression (885 views)
J Cell Physiol (ISSN: 1097-4652electronic, 0021-9541linking), 2018 Jan 18; 233(8): 6241-6249.
Impact Factor: 5.546
View    Export to BibTeX    Export to EndNote

Brancaccio D, Diana D, Di Maro S, Di Leva FS, Tomassi S, Fattorusso R, Russo L, Scala S, Trotta AM, Portella L, Novellino E, Marinelli L, Carotenuto A
* Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer Cells (1258 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2018; 61(7): 2910-2923.
Impact Factor: 5.207
View    Export to BibTeX    Export to EndNote

Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ierano C, Cerchia L, Lucarelli E, Scala S, Zannetti A
* A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion (1071 views) (PDF 305 views)
Cancer Lett (ISSN: 0304-3835), 2015 Oct 27; 370(1): 100-107.
Impact Factor: 7.36
View    Export to BibTeX    Export to EndNote

Calce E, Vitale RM, Scaloni A, Amodeo P, De Luca S
* Air oxidation method employed for the disulfide bond formation of natural and synthetic peptides (717 views)
Amino Acids (ISSN: 0939-4451, 1438-2199, 1438-2199electronic), 2015; 47(8): 1507-1515.
Impact Factor: 3.196
View    Export to BibTeX    Export to EndNote

Vincenzi M, Costantini S, Scala S, Tesauro D, Accardo A, Leone M, Colonna G, Guillon J, Portella L, Trotta AM, Ronga L, Rossi F
* Conformational ensembles explored dynamically from disordered peptides targeting chemokine receptor CXCR4 (726 views)
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2015; 16(6): 12159-12173.
Impact Factor: 3.257
View    Export to BibTeX    Export to EndNote

Neve Polimeno M, Ierano C, D'Alterio C, Simona Losito N, Napolitano M, Portella L, Scognamiglio G, Tatangelo F, Maria Trotta A, Curley S, Costantini S, Liuzzi R, Izzo F, Scala S
* CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not (814 views)
Cell Mol Immunol (ISSN: 1672-7681), 2014 Nov 3; 12(4): 474-482.
Impact Factor: 4.112
View    Export to BibTeX    Export to EndNote

D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S
* A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients (560 views)
Int J Cancer (ISSN: 0020-7136), 2014 Jul 15; 135(2): 379-390.
Impact Factor: 5.085
View    Export to BibTeX    Export to EndNote

Lusso P, Vangelista L, Cimbro R, Secchi M, Sironi F, Longhi R, Faiella M, Maglio O, Pavone V
* Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity (718 views)
Faseb J (ISSN: 0892-6638, 0892-6638linking), 2011 Apr; 25(4): 1230-1243.
Impact Factor: 5.712
View    Export to BibTeX    Export to EndNote

Napolitano M, Ottaiano A, Mauro F, Ieranò C, Satriano R, Pacelli R, Franco R, De Angelis V, Castello G, Scala S
* CD4(+)CD45RA(+)CXCR4(+) lymphocytes are inversely associated with progression in stages I-III melanoma patients (463 views)
Cancer Immunol Immunother (ISSN: 0340-7004, 0340-7004linking), 2010 Apr; 59(4): 511-517.
Impact Factor: 4.293
View    Export to BibTeX    Export to EndNote

Ierano C, Giuliano P, D'Alterio C, Cioffi M, Mettivier V, Portella L, Napolitano M, Barbieri A, Arra C, Liguori G, Franco R, Palmieri G, Rozzo C, Pacelli R, Castello G, Scala S
* A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration (447 views)
Cell Cycle (ISSN: 1538-4101), 2009 Apr 15; 8(8): 1228-1237.
Impact Factor: 4.087
View    Export to BibTeX    Export to EndNote

Palladino P, Tizzano B, Pedone C, Ragone R, Rossi F, Saviano G, Tancredi T, Benedetti E
* Structural determinants of unexpected agonist activity in a retro-peptide analogue of the SDF-1α N-terminus (577 views)
Febs Lett (ISSN: 0014-5793, 0014-5793print, 1873-3468electronic), 2005 Oct 10; 579(24): 5293-5298.
Impact Factor: 3.415
View    Export to BibTeX    Export to EndNote

Palladino P, Pedone C, Ragone R, Rossi F, Saviano M, Benedetti E
* A simplified model of the binding interaction between stromal cell-derived factor-1 chemokine and CXC chemokine receptor (443 views)
Protein Pept Lett (ISSN: 0929-8665, 1875-5305), 2003 Apr; 10(2): 133-138.
Impact Factor: 0.46
View    Export to BibTeX    Export to EndNote

Palladino P, De Capua A, Pedone C, Ragone R, Rossi F, Limatola C, Ragozzino D, Benedetti E
* A simplified model of the interaction between SDF-1 chemokine and the CXCR4 receptor (572 views)
Peptide Revolution, 2003 Apr; 10(2): 133-138.
Impact Factor: 4.659
View    Export to BibTeX    Export to EndNote

13 Records (13 excluding Abstracts).
Total impact factor: 56.389 (56.389 excluding Abstracts).
Total 5 year impact factor: 50.003 (50.003 excluding Abstracts).

Last modified by Marco Comerci on Tuesday 09 April 2024, 12:56:55
586 views. Last view on Friday 11 October 2024, 19:43:35